Table 4.
History of cancer in patients with COVID-19
| All patients (n=205) | Survivors (n=165) | Non-survivors (n=40) | p value | ||
|---|---|---|---|---|---|
| Cancer type | |||||
| Haematological malignancy | 22 (11%) | 13 (8%) | 9 (23%) | 0·017* | |
| Lymphoma | 7 (3%) | 4 (2%) | 3 (8%) | .. | |
| Acute lymphoblastic leukaemia | 5 (2%) | 2 (1%) | 3 (8%) | .. | |
| Chronic lymphoblastic leukaemia | 4 (2%) | 4 (2%) | 0 | .. | |
| Multiple myeloma | 3 (1%) | 1 (1%) | 2 (5%) | .. | |
| Acute myelogenous leukaemia | 2 (1%) | 1 (1%) | 1 (3%) | .. | |
| Myelodysplastic syndrome | 1 (<1%) | 1 (1%) | 0 | .. | |
| Solid tumour | 183 (89%) | 152 (92%) | 31 (78%) | .. | |
| Breast | 40 (20%) | 37 (22%) | 3 (8%) | .. | |
| Colorectal | 28 (14%) | 22 (13%) | 6 (15%) | .. | |
| Lung | 24 (12%) | 18 (11%) | 6 (15%) | .. | |
| Thyroid | 16 (8%) | 15 (9%) | 1 (3%) | .. | |
| Stomach | 12 (6%) | 9 (5%) | 3 (8%) | .. | |
| Cervical | 9 (4%) | 9 (5%) | 0 | .. | |
| Other† | 54 (26%) | 42 (25%) | 12 (30%) | .. | |
| History of treatments | |||||
| Surgery | 140/182 (77%) | 121/148 (82%) | 19/34 (56%) | 0·0027 | |
| Chemotherapy | 104/182 (57%) | 76/148 (51%) | 28/34 (82%) | 0·0019 | |
| Radiotherapy | 37/182 (20%) | 30/148 (20%) | 7/34 (21%) | 1·00 | |
| Targeted therapy | 18/182 (10%) | 10/148 (7%) | 8/34 (24%) | 0·0084 | |
| Immunotherapy | 7/182 (4%) | 4/148 (3%) | 3/34 (9%) | 0·24 | |
| Treatments within 4 weeks before symptom onset | |||||
| All | 54/182 (30%) | 36/148 (24%) | 18/34 (53%) | 0·0020 | |
| Surgery | 4/182 (2%) | 4/148 (3%) | 0 | 0·75 | |
| Chemotherapy | 31/182 (17%) | 16/148 (11%) | 15/34 (44%) | <0·0001 | |
| Radiotherapy | 9/182 (5%) | 6/148 (4%) | 3/34 (9%) | 0·47 | |
| Targeted therapy | 12/182 (7%) | 6/148 (4%) | 6/34 (18%) | 0·013 | |
| Immunotherapy | 4/182 (2%) | 2/148 (1%) | 2/34 (6%) | 0·33 | |
| Others‡ | 10/182 (5%) | 10/148 (7%) | 0 | 0·25 | |
| Cancer stage | |||||
| I–II | 109/149 (73%) | 98/127 (77%) | 11/22 (50%) | 0·017 | |
| III–IV | 40/149 (27%) | 29/127 (23%) | 11/22 (50%) | .. | |
| Time since cancer diagnosis | |||||
| <1 years | 38/192 (20%) | 24/156 (15%) | 14/36 (39%) | 0·0006 | |
| 1–5 years | 75/192 (39%) | 59/156 (38%) | 16/36 (44%) | .. | |
| >5 years | 79/192 (41%) | 73/156 (47%) | 6/36 (17%) | .. | |
| ECOG performance status score | |||||
| 0 | 101/162 (62%) | 85/132 (64%) | 16/30 (53%) | 0·36 | |
| 1 | 41/162 (25%) | 33/132 (25%) | 8/30 (27%) | .. | |
| 2 | 12/162 (7%) | 9/132 (7%) | 3/30 (10%) | .. | |
| 3 | 7/162 (4%) | 4/132 (3%) | 3/30 (10%) | .. | |
| 4 | 1/162 (1%) | 1/132 (1%) | 0 | .. | |
Data are n (%) or n/N (%), where N is the number of patients with available data. ECOG=Eastern Cooperative Oncology Group.
*
χ2 test for haematological malignancy and solid tumour.
†
Other cancer types included liver, ovarian, prostate, and other cancers.
‡
Other therapies included endocrinotherapy and traditional Chinese medicine.